Pharma and biotech: the patentability of in silico inventions before the EPO
Marion Autissier, Denis Bourgarel
When modeling replaces the laboratory in the biomedical field
An “in silico” invention is an (...)
Sandrine Bouvier-Ravon, François Jonquères
A year ago, Sandrine Bouvier-Ravon and François Jonquères, partners at Plasseraud IP Avocats, co- (...)
Bruno Loubet
T0799/24 “JFESteel”: an explicit manufacturing step is not mandatory to provide a technical effect (...)
Bruno Loubet
One of the key requirements that a European application must fulfill is the criterion of (...)
Bruno Loubet
At the European Patent Office (EPO), computer-implemented inventions, especially those involving (...)
Lilia Leghmizi
On 27 June 2023, in case T 438/19, Technical Board 3.3.03 referred key questions to the Enlarged (...)
Bruno Loubet
The decision T 1580/23 of the Boards of Appeal 3.5.05 of the European Patent Office (EPO) is an (...)
Nadine Rocaboy, Oung-Heng Heng
The Enlarged Board of Appeal’s recent decision in G 1/24 has provided significant clarification (...)
Guillaume Vermander, Claire Herissay-Ducamp
I - AI tools, new tools for creators...
If we put the question "AI tools, new tools for creators (...)
Louis Lavigne, Bruno Loubet
In a recent decision T 1193/23 - 3.2.06 by the Boards of Appeal of the European Patent Office (EPO (...)
紹介資料を開く